©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 21, 2023; 29(7): 1131-1138
Published online Feb 21, 2023. doi: 10.3748/wjg.v29.i7.1131
Published online Feb 21, 2023. doi: 10.3748/wjg.v29.i7.1131
Tranexamic acid may be a useful pharmacotherapy for endoscopically resistant small bowel angiodysplasia
Shunji Fujimori, Department of Gastroenterology, Chiba Hokusoh Hospital, Nippon Medical School, Chiba 270-1694, Japan
Author contributions: Fujimori S contributed to the writing of this paper.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Corresponding author: Shunji Fujimori, AGAF, MD, PhD, Director, Department of Gastroenterology, Chiba Hokusoh Hospital, Nippon Medical School, 1715, Kamagari, Inzai-City, Chiba 270-1694, Japan. s-fujimori@nms.ac.jp
Received: November 5, 2022
Peer-review started: November 5, 2022
First decision: November 17, 2022
Revised: November 23, 2022
Accepted: January 31, 2023
Article in press: January 31, 2023
Published online: February 21, 2023
Processing time: 107 Days and 16.6 Hours
Peer-review started: November 5, 2022
First decision: November 17, 2022
Revised: November 23, 2022
Accepted: January 31, 2023
Article in press: January 31, 2023
Published online: February 21, 2023
Processing time: 107 Days and 16.6 Hours
Core Tip
Core Tip: It is difficult to treat all multiple small bowel angiodysplasias (SBAD) endoscopically. Four main types of drugs, including somatostatin analogs, hormone therapy, thalidomide, and vascular endothelial growth factor-neutralizing antibodies, have been reported for use in gastrointestinal angiodysplasias (GIAD). However, there is no recommended pharmacotherapy for SBAD. Tranexamic acid is recommended for patients with GIAD in hereditary hemorrhagic telangiectasia who are difficult to treat endoscopically. Investigation of the use of tranexamic acid for SBAD is desired.